Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  














Susoctocog alfa







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Susoctocog alfa
Clinical data
Trade namesObizur
Other namesAntihemophilic factor (recombinant)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • Drug classAntihemophilic factor
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)[2]
  • CA: ℞-only[3]
  • UK: POM (Prescription only)[4]
  • US: ℞-only[5]
  • EU: Rx-only[6]
  • In general: ℞ (Prescription only)
  • Identifiers
    CAS Number
    DrugBank
    UNII
    KEGG

    Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.[6][5][7]

    Susoctocog alfa was approved for medical use in the United States in October 2014,[8][9] and for medical use in the European Union in November 2015.[6]

    Factor VIII is one of the proteins needed for normal clotting of the blood.[6]

    References[edit]

    1. ^ "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Retrieved 6 March 2020.
  • ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  • ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
  • ^ "Obizur 500 U powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 13 April 2017. Retrieved 3 September 2020.
  • ^ a b "Obizur (antihemophilic factor- recombinant, porcine sequence kit". DailyMed. 2 January 2020. Retrieved 6 March 2020.
  • ^ a b c d "Obizur EPAR". European Medicines Agency. 6 March 2020. Retrieved 6 March 2020.
  • ^ Burness CB, Scott LJ (May 2016). "Susoctocog Alfa: A Review in Acquired Haemophilia A". Drugs. 76 (7): 815–21. doi:10.1007/s40265-016-0576-1. PMID 27098420. S2CID 10880049.
  • ^ "Obizur". U.S. Food and Drug Administration (FDA). 13 March 2018. Archived from the original on 23 April 2019. Retrieved 6 March 2020.
  • ^ "Obizur". U.S. Food and Drug Administration (FDA). 27 September 2019. STN: BL 125512. Retrieved 6 March 2020.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Susoctocog_alfa&oldid=1218180350"

    Categories: 
    Antihemorrhagics
    Blood and blood forming organ drug stubs
    Hidden categories: 
    Use dmy dates from March 2020
    Drugs with non-standard legal status
    Infobox drug articles without a structure image
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Articles without InChI source
    Articles containing unverified chemical infoboxes
    All stub articles
     



    This page was last edited on 10 April 2024, at 06:01 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki